Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

There is no cure for myotonic dystrophy type 1, so treatment focuses on managing symptoms and complications.

Many young women in Pakistan are unaware of their PCOS symptoms.

The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.

Women with PCOS have worse physical health but similar mental health compared to those without PCOS.

Alopecia causes emotional distress, and better psychological support is needed.

Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.

Many women experience sexual dysfunction, but few seek help, and better treatment and medical training are needed.

Breast implants are linked to autoimmune symptoms, with over half of patients feeling better after removal, but the exact cause is unclear and may involve bacterial biofilm.

Adaptive coping reduces PCOS symptoms, while maladaptive coping worsens them.

The guidelines recommend informed consent for gender-affirming treatments and stress the importance of personalized, culturally sensitive care for transgender individuals.

Male hormones may play a role in the development of heart disease, and more research is needed to understand their effects.

While PCOS might increase the risk of heart disease, there's not strong evidence to prove it causes earlier heart problems.

Polycystic ovary syndrome costs the U.S. over $4 billion a year, mainly from treating related health issues.

PCOS is common among Chinese women of reproductive age and linked to serious metabolic and reproductive issues, especially in obese women.

The Rotterdam Study aims to understand disease causes in the elderly and has found new risk factors and genetic influences on various conditions.

PCOS is a complex disorder in women that can lead to various health risks and requires personalized treatment.

The NAMS 2014 recommendations guide healthcare providers on treating health issues in midlife women, emphasizing individualized care and informed decision-making.

MK-0773 safely increased muscle mass but did not improve muscle strength or function in elderly women with sarcopenia.

Hormone treatments for transgender individuals generally improve mental health and physical transition, with some health risks that require medical supervision.

Chemotherapy-induced hair loss significantly affects patients' well-being, and nurses are key in helping them cope, but more research is needed to find effective treatments.

Microneedles help improve skin appearance and deliver skin treatments effectively, but safety concerns need more research and regulation.

The skin's internal clock affects healing, cancer risk, aging, immunity, and hair growth, and disruptions can harm skin health.

A new genetic region, 17q21.31, is linked to higher ovarian cancer risk.

Women with PCOS are more likely to suffer from depression, anxiety, and stress.

Hair mineral analysis might help diagnose diseases early, but standard methods are needed.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

People with diabetes or obesity should manage their conditions carefully as they have a higher risk of severe COVID-19.

Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.

The review recommends hormone replacement therapy for women with premature ovarian insufficiency to manage symptoms and protect health, with specific approaches for different groups.

High doses of cyproterone acetate increase the risk of brain tumors in women, but the risk decreases after stopping the medication.